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The histone H3K9 methyltransferase SUV39H links
SIRT1 repression to myocardial infarction
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Myocardial infarction (MI) dampens heart function and poses a great health risk. The class III
deacetylase sirtuin 1 (SIRT1) is known to confer cardioprotection. SIRT1 expression is
downregulated in the heart by a number of stress stimuli that collectively drive the patho-
genesis of MI, although the underlying mechanism remains largely obscure. Here we show
that in primary rat neonatal ventricular myocytes (NRVMs), ischaemic or oxidative stress
leads to a rapid upregulation of SUV39H, the mammalian histone H3K9 methyltransferase,
paralleling SIRT1 downregulation. Compared to wild-type littermates, SUV39H knockout mice
are protected from MI. Likewise, suppression of SUV39H activity with chaetocin attenuates
cardiac injury following MI. Mechanistically, SUV39H cooperates with heterochromatin
protein 1 gamma (HP1g) to catalyse H3K9 trimethylation on the SIRT1 promoter and
represses SIRT1 transcription. SUV39H augments intracellular ROS levels in a SIRT1-depen-
dent manner. Our data identify a previously unrecognized role for SUV39H linking SIRT1
trans-repression to myocardial infarction.
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A
number of factors, including senescence, unhealthy
dietary choices and life styles, and surges in metabolic
disorders, all contribute to the epidemic of ischaemic
heart disease (IHD) across a wide spectrum of ages and ethnic
groups worldwide. Despite decades of vigorous basic and clinical
research, IHD remains the leading cause of death in major
industrialized nations1. Myocardial infarction (MI), spontaneous
or procedural, in patients with IHD, serves to further depress
heart function, frequently induces deleterious cardiac
remodelling, aggravates organ ischaemia, and is associated with
increased risk of heart failure and mortality2. Clearly, deciphering
the mechanisms that drive the pathogenesis of MI holds the
key to stabilizing heart function and reducing MI-related deaths
in IHD patients.
During MI pathogenesis, a host of stress stimuli inflict injuries
in cardiomyocytes. Ischaemia depletes cellular ATP causing
mitochondrial dysfunction and accelerating reactive oxygen
species (ROS) generation. Elevated ROS levels, in turn, interfere
with oxidative phosphorylation and dampen mitochondrial
function creating a self-amplifying vicious cycle to drive the
death of cardiomyocytes3. By comparison, anti-oxidant therapies
have shown varied but promising effects in alleviating
MI-induced heart injury in model animals and in IHD
patients4,5. The class III protein deacetylase SIRT1 has been
documented to confer cardioprotection in the context of IHD
both in vivo and in vitro at least in part by suppressing ROS
generation6–9. In keeping with these observations, SIRT1
expression levels and, by extension, promoter polymorphisms
have been found to correlate with acute MI in model animals and
in humans10–12. The underlying mechanism contributing to
altered SIRT1 transcription in ischaemic cardiomyocytes is not
understood.
The epigenetic machinery plays a pivotal role in regulating
mammalian gene expression. Differential histone modifications
represent a prototypical epigenetic mechanism wherein a
combination of several modified residues on histone tails
barcodes the promoter region and predicts the transcriptional
outcome of a specific gene. A simplistic model has been proposed
that, confirmed more recently through genome-wide sequencing
analyses, trimethylation of histone H3 lysine 4 (H3K4Me3)
heralds transcriptional activation, whereas trimethylation of H3
lysine 9 (H3K9Me3) leads to trans-repression. SUV39H, short for
suppressor of variegation 3(9) homologue, is the sole enzyme
responsible for laying down the H3K9Me3 mark on the
chromatin13. SUV39H was initially discovered as essential for
silencing gene expression in the heterochromatin region. It
remains obscure how SUV39H may contribute to gene regulation
in the euchromatin region and more importantly, to the
pathogenesis of MI.
We report here that upregulation of SUV39H accompanies
SIRT1 downregulation in the heart during MI. Genetic deletion
or pharmaceutical inhibition of SUV39H ameliorates cardiac
injury following MI in mice. SUV39H modulates ROS levels in
the heart in a SIRT1-dependent manner. Therefore, SUV39H
links SIRT1 trans-repression to myocardial infarction providing
rationale for targeting SUV39H1 in the development novel
therapeutic strategies to treat ischaemic heart disease.
Results
SUV39H levels are upregulated in vivo and in vitro. We started
off by examining the levels of SUV39H in the myocardium
following ischaemia challenge in mice. As shown in Fig. 1a, there
was a quick increase in Suv39h1 mRNA levels in ischaemic hearts
in mice 12 h after the ligation of left anterior descending (LAD)
artery procedure, which was sustained and further augmented at
4 and 7 days. Suv39h2mRNA levels were also upregulated in
ischaemic hearts at 12 h but receded at 4 and 7 days. Western
blotting showed a similar trend in the protein levels of Suv39h1
and Suv39h2 following MI (Fig. 1b). We also examined the
expression levels of heterochromatin protein 1 (HP1), the binding
partner for SUV39H during heterochromatinzation and gene
trans-repression13. The Hp1a and Hp1b isoforms were not
significantly altered in the heart throughout the observation
window of 7 days following MI, but the Hp1g isoform was
upregulated at day 4 and day 7 post MI in ischaemic heart tissues
(Supplementary Fig. 1).
In primary rat neonatal ventricular myocytes (NRVMs),
ischaemic stress (Fig. 2a,b), simulated by the addition of
antimycin A plus 2-deoxy glucose (AAþ 2-DG) to deplete
intracellular ATP14, and oxidative stress (Fig. 2c,d), induced by
the addition of hydrogen peroxide (H2O2) (refs 15,16), both
stimulated the expression of Suv39h1 and, to a lesser extent,
Suv39h2. Similar observations were made in an immortalized rat
myoblast cell line H9C2 (Supplementary Fig. 2). Taken together,
we conclude that SUV39H levels are responsive to MI-relevant
stimuli in the heart and cultured cardiomyocytes indicative of a
potential role for SUV39H in MI pathogenesis.
SUV39H deficiency protects against MI in mice. To assign a role
for SUV39H in MI pathogenesis, we performed the following
experiments. MI was induced in Suv39h1 knockout (Suv39h1 / )
mice, Suv39h2 knockout (Suv39h2 / ) mice or wide-type (WT)
littermates by the LAD procedure. Kaplan–Meier analysis indicated
that both Suv39h1 / and Suv39h2 / mice had a significant
advantage of survival over WT mice post MI; additionally,
Suv39h1 / mice survived significantly longer than Suv39h2 /
mice (Fig. 3a). Post-mortem autopsy revealed that while both
Suv39h1 / and Suv39h2 / mice had fewer incidents of car-
diac rupture than WT mice, Suv39h1 / mice were less prone to
cardiac rupture than Suv39h2 / mice (Supplementary Table 1).
Quantitative PCR and western blotting indicated that matrix
metalloproteinase 9 (MMP9) induction following MI was much
more prominent in WT mice than in either Suv39h1 / mice or
Suv39h2 / mice (Supplementary Fig. 3). Indeed, both
Suv39h1 / mice and Suv39h2 / mice had a smaller infarct
size than WT littermates (Fig. 3b,c). TUNEL assay provided
corroborating evidence, which suggested that there was more
extensive cardiomyocyte death in WT mice as compared to
Suv39h1 / mice or Suv39h2 / mice (Supplementary Fig. 4).
These observations probably explained why Suv39h1 / and
Suv39h2 / mice exhibited better heart functions as evidenced by
echocardiographic assessment of EF (Fig. 3d) and FS (Fig. 3e)
values.
Since deficient ROS elimination plays a role in MI pathogenesis,
we evaluated the effect of SUV39H deficiencies on ROS
levels in vivo. As shown in Fig. 3f, dihydroethidium (DHE)
staining demonstrated that ROS accumulation was much
stronger in WT hearts than either Suv39h1 / or Suv39h2 /
hearts. Furthermore, SUV39H deficiencies significantly attenuated
the down-regulation of several anti-oxidant genes including
superoxide dismutase 1 (Sod1), superoxide dismutase 2 (Sod2)
and catalase (Cat) in the myocardium following MI (Fig. 3g,h).
To probe a myeloid lineage-specific role for SUV39H in
myocardial infarction, we performed bone marrow transplanta-
tion assay. To this end, MI was induced in wild-type mice
receiving bone marrow from either wild-type, Suv39h1 / or
Suv39h2 / mice. Post-mortem autopsy revealed that there was
no significant difference in terms of infarct size; nor was there any
improvement in post-MI heart function (Supplementary Fig. 5).
Consistently, expression levels of anti-oxidant genes and cardiac
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Figure 1 | SUV39H levels were upregulated in the heart following MI. (a,b) MI was induced in C57/BL6 mice by the LAD procedure and the mice were
killed at indicated time points. Heart issues from the infarcted area (IA) and the non-infarcted area (NIA) were homogenized and examined for SUV39H
and SIRT1 expression by qPCR and western blotting. Error bars represent s.d. (N¼6 for the sham group and N¼ 10 for each of the MI groups). *Po0.05;
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Figure 2 | SUV39H were upregulated by ischaemic and oxidative stimuli in cardiomyocytes. (a,b) Primary rat neonatal ventricular myocytes (NRVMs)
were treated with AAþ 2-DG and harvested at indicated time points. Expression levels were examined by qPCR (a) and western blotting (b). (c,d) Primary
NRVMs were treated with H2O2 and harvested at indicated time points. Expression levels were examined by qPCR (c) and western blotting (d). Error bars
represent s.d. (N¼ 3). *Po0.05 (one-way ANOVA with post hoc Scheffe test).
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Figure 3 | SUV39H deficiency protects against MI in mice. MI was induced in Suv39h1 knockout (h1 / ) mice, Suv39h2 knockout (h2 / ) mice or
wide-type (WT) littermates by LAD. (a) Kaplan–Meier plot showing the survival rates up to 7 days after MI. (b) Representative TTC staining. (c) Infarct
size was calculated and quantified by Image Pro. Error bars represent s.d (N¼ 6 for the sham group and N¼ 10 for each of the MI groups). (d,e) EF and FS
values were measured by echocardiography. Error bars represent s.d. (N¼4 for the sham group and N¼ 8 for each of the MI groups). (f) Cardiac ROS
levels were evaluated by DHE staining. Scale bar, 50mm. Error bars represent s.d. (N¼ 3 for the sham group and N¼6 for each of the MI groups).
(g,h) Expression levels of anti-oxidant genes were measured by qPCR (g) and western blotting (h). Error bars represent s.d. (N¼4 for the sham group and
N¼ 8 for each of the MI groups). *Po0.05; **Po0.01 (one-way ANOVA with post hoc Scheffe test).
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ROS levels were not significantly altered among three different
chimeric mice (Supplementary Fig. 6). Taken together, these data
strongly support a role for SUV39H in promoting MI in mice.
SUV39H inhibition attenuates MI in mice. Next, we sought
additional evidence that SUV39H might play a role in the
pathogenesis of MI. To this end, male C57/BL6 mice were
injected peritoneally with chaetocin, a reported inhibitor of
SUV39H activity17, or DMSO prior to the LAD procedure.
Histone methyltransferase assays performed using heart tissue
homogenates indicated that chaetocin injection markedly
inhibited the activities of both SUV39H1 and SUV39H2 in
mice (Supplementary Fig. 7). Chaetocin administration
significantly improved the survival rate of mice (Fig. 4a) and
reduced infarct size (Fig. 4b,c). Accompanying these changes
there was a reduction in Mmp9 expression, as measured by qPCR
and western blotting (Supplementary Fig. 8A,B), and
cardiomyocyte apoptosis, as measured by TUNEL assay
(Supplementary Fig. 8C), in the heart following MI. DHE
staining showed that cardiac ROS levels were suppressed by
chaetocin administration (Fig. 4d). Furthermore, chaetocin
administration was able to rescue the repression of anti-oxidant
genes by MI (Fig. 4e,f). These protective effects afforded by
chaetocin cumulatively contributed to improved post-MI heart
function (Fig. 4g,h).
We also evaluated the effect of chaetocin on cardiac
remodelling 4 weeks after infarction. Picrosirius red and Masson’s
trichrome staining showed that chaetocin ameliorated interstitial
fibrosis (Supplementary Fig. 9A). qPCR and western blotting
measurements confirmed that chaetocin pre-empted the induc-
tion of pro-fibrogenic genes including type I collagen and alpha
smooth muscle actin (a-SMA) in MI hearts (Supplementary
Fig. 9B,C). Collectively, these data argue that SUV39H inhibition
could not only reduce infarction but also block adverse cardiac
remodelling in mice.
SUV39H represses SIRT1 transcription. Next, we tackled the
mechanism whereby SUV39H may contribute to MI pathogen-
esis. SIRT1 has been assigned a cardiac-protective role and its
expression is inversely correlated with acute MI in humans. Of
interest, we observed an inverse correlation between SUV39H
expression and SIRT1 expression in mice (Fig. 1). Thus, we
proposed that SUV39H might promote MI by targeting SIRT1.
To verify this hypothesis, we performed the following experi-
ments. Reporter assays (Supplementary Fig. 10A) showed that
SUV39H1 was able to repress the activity of the shortest SIRT1
promoter ( 115/þ 54). In a parallel experiment, we found that
ecotopic (Myc-tagged) SUV39H could indeed bind to and con-
sequently stimulate the accumulation of trimethylated H3K9 on
the reporter construct transfected into H9C2 cells (Supplemen-
tary Fig. 10B). Chromatin immunoprecipitation (ChIP) assay
showed that following AAþ 2-DG stimulation, SUV39H1
quickly assembled on this region of the Sirt1 promoter but not the
Gapdh promoter in both NRVMs (Fig. 5a) and H9C2 cells
(Supplementary Fig. 11A); by comparison, SUV39H2 was
recruited with much weaker affinity. Of interest, there was no
significant enrichment of either SUV39H1 or SUV39H2 on the
Sod1 promoter despite strong trans-repression by AAþ 2-DG
treatment, indicating that SUV39H might regulate Sod1 tran-
scription indirectly. Paralleling SUV39H binding, trimethylated
histone H3K9 started to accumulate on the Sirt1 promoter while
acetylated H3K9, an antagonistic marker to H3K9Me3, departed
from the Sirt1 promoter consistent with its trans-repression.
Similar observations were made with H2O2 treatment (Fig. 5b,
Supplementary Fig. 11B). We did not detect significant enrich-
ment of H3K9Me2, another prominent histone modification
associated with repressed chromatin, on the Sirt1 promoter
suggesting that H3K9Me2 might not play a role in SIRT1 trans-
repression in the context of MI. Unlike HP1a and HP1b, HP1g
exhibited enhanced binding to the Sirt1 promoter (but not to the
Gapdh promoter or the Sod1 promoter) in NRVMs treated with
either AAþ 2-DG or H2O2 (Supplementary Fig. 12). In keeping
with this observation, HP1g also formed a complex with
SUV39H1 and SUV39H2 (albeit with lower affinity than
SUV39H1) on the Sirt1 promoter as evidenced by Re-ChIP assay
(Supplementary Fig. 13).
More importantly, we discovered that SUV39H1 and
SUV39H2 were recruited to the Sirt1 promoter and interacted
specifically with HP1g in the infarcted myocardium in mice
(Fig. 5c, Supplementary Fig. 14), suggesting that SUV39H
probably serves as a common link to SIRT1 trans-repression.
Finally, reporter assay confirmed that SUV39H1 not only dose-
dependently repressed the Sirt1 promoter but also enhanced the
trans-repression of Sirt1 promoter by either AAþ 2-DG
(Supplementary Fig. 15A) or H2O2 (Supplementary Fig. 15B).
Again, of the three HP1 isoforms only HP1g repressed the Sirt1
promoter in the presence of either AAþ 2-DG or H2O2
(Supplementary Fig. 16A–C). Using ChIP assay, we confirmed
that ectopically introduced (HA-tagged) HP1g could indeed
occupy the SIRT1 reporter construct in H9C2 cells
(Supplementary Fig. 16D). Therefore, we conclude that SUV39H
represses Sirt1 transcription in cardiomyocytes.
SUV39H silencing or inhibition restores SIRT1 transcription.
We next employed the following strategies to confirm that
SUV39H is indispensible for SIRT1 trans-repression in the con-
text of MI. siRNA-mediated knockdown of SUV39H1 or
SUV39H2 abrogated H3K9Me3 assembly and restored H3K9Ac
levels on the Sirt1 promoter despite the stimulation by AAþ 2-
DG in cardiomyocytes (Fig. 6a, Supplementary Fig. 17A).
Accordingly, SUV39H knockdown normalized Sirt1 expression at
both mRNA (Fig. 6b, Supplementary Fig. 17B) and protein
(Fig. 6c, Supplementary Fig. 17C) levels. Likewise, SUV39H
depletion also remodelled the chromatin structure surrounding
the Sirt1 promoter (Fig. 6d, Supplementary Fig. 18A) and
restored Sirt1 expression (Fig. 6e,f, Supplementary Fig. 18B,C) in
H2O2-treated cardiomyocytes. In SUV39H1 and SUV39H2 defi-
cient mice, we observed more H3K9Ac and less H3K9Me3 on the
Sirt1 promoter as opposed to WT mice (Fig. 6g), which probably
contributed to higher SIRT1 levels in infarcted hearts (Fig. 6h,i).
Consistent with the prior observations that HP1g interacted with
SUV39H to repress Sirt1 transcription, silencing of HP1g, but not
HP1a or HP1b, with siRNA led to partial restoration of Sirt1
expression in NRVMs exposed to either AAþ 2-DG or H2O2
(Supplementary Fig. 19). HP1g silencing also led to the normal-
ization of anti-oxidant genes accompanying erasure of trimethyl
H3K9 and restoration of acetyl H3K9 on the Sirt1 promoter in
both AAþ 2-DG (Supplementary Fig. 20) and H2O2-treated
(Supplementary Fig. 21) NRVMs.
We then used chaetocin to inhibit SUV39H activity to validate
the role of SUV39H in SIRT1 trans-repression. Indeed, chaetocin
treatment simultaneously blocked H3K9Me3 accumulation and
H3K9Ac erasure on the Sirt1 promoter and dose-dependently
upregulated SIRT1 in cardiomyocytes challenged with AAþ
2-DG (Fig. 7a–c, Supplementary Fig. 22) or H2O2 (Fig. 7d–f,
Supplementary Fig. 23). Chaetocin injection in C57/BL6 mice
resulted in a more active chromatin structure surrounding the
Sirt1 promoter (Fig. 7g) and increased SIRT1 expression in
infarcted hearts (Fig. 7h,i).
SUV39H regulates ROS generation in a SIRT1-dependent manner.
Having established that SUV39H promotes ROS generation and
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Figure 4 | SUV39H inhibition attenuates MI in mice. C57/BL mice were injected peritoneally with chaetocin (25mg kg 1) or DMSO 2 days prior to the
LAD procedure. (a) Kaplan–Meier plot showing the survival rates up to 7 days after MI. (b) Representative TTC staining. (c) Infarct size was calculated and
quantified by Image Pro. Error bars represent s.d. (N¼ 8 for the sham group and N¼ 10 for each of the MI groups). (d) Cardiac ROS levels were evaluated
by DHE staining. Scale bar, 50mm. Error bars represent s.d. (N¼ 3 for the sham group and N¼ 6 for each of the MI groups). (e,f) Expression levels of anti-
oxidant genes were measured by qPCR (g) and western blotting (h). Error bars represent s.d. (N¼4 for the sham group and N¼ 6 for each of the MI
groups). (g,h) EF and FS values were measured by echocardiography. Error bars represent s.d. (N¼4 for the sham group and N¼ 8 for each of the MI
groups). *Po0.05; **Po0.01; ***Po0.001 (one-way ANOVA with post hoc Scheffe test).
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SIRT1 trans-repression in the process of myocardial infarction,
we asked whether the ability of SUV39H to regulate ROS levels in
cardiomyocytes depends on SIRT1. As shown in Fig. 8a and
Fig. 8b, depletion of SUV39H blocked the downregulation of
Sod1, Sod2 and Cat by AAþ 2-DG treatment, which was pre-
empted by siRNA-mediated SIRT1 silencing. Consistent with
gene expression levels, DHE staining showed that SUV39H
silencing prevented the induction of intracellular ROS generation
by AAþ 2-DG, which was abrogated by SIRT1 inhibition
(Fig. 8c). Similar results were obtained in cardiomyocytes treated
with H2O2 (Supplementary Fig. 24). A specific SIRT1 inhibitor
EX-527 achieved similar effects (Supplementary Figs 25 and 26).
In the second set of experiments, inhibition of SUV39H activity
by chaetocin alleviated the decrease of anti-oxidant gene
expression by AAþ 2-DG (Fig. 8d,e) and the increase in
intracellular ROS levels (Fig. 8f), both of which were neutralized
by SIRT1 knockdown. Again, we were able to confirm that the
anti-oxidative effects endowed by chaetocin were completely lost
without endogenous SIRT1 activity in H2O2-treated NRVMs
(Supplementary Fig. 27). Likewise, EX-527 treatment also negated
the effects of chaetocin in both AAþ 2-DG (Supplementary
Fig. 28) and H2O2-treated (Supplementary Fig. 29) NRVMs.
Finally, we analysed whether this SUV39H–SIRT1 axis might
be functional in mice. To this end, SUV39H knockout mice or
wild-type littermates were injected via tail vein siRNA targeting
SIRT1 or scrambled siRNA prior to the MI procedure. SIRT1
silencing almost completely blanketed the reduction in infarction
size (Fig. 9a) and the improvement of post-MI heart function
(Fig. 9b,c) as a result of SUV39H deficiency. qPCR and western
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Figure 5 | SUV39H represses SIRT1 transcription. (a,b) Primary NRVMs were treated with AAþ 2-DG (a) or H2O2 (b). ChIP assays were performed with
indicated antibodies. (c) ChIP assays were performed with heart homogenates fromMI mice or sham mice. Error bars represent s.d. (N¼ 3 for each group).
*Po0.05; **Po0.01 (one-way ANOVA with post hoc Scheffe test).
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Figure 6 | SUV39H silencing restores SIRT1 transcription. (a–c) Primary NRVMs were transfected with SUV39H siRNA or random siRNA (SCR) followed
by treatment with AAþ 2-DG. ChIP assays were performed with indicated antibodies (a). SIRT1 expression was examined by qPCR (b) and western
blotting (c). (d–f) Primary NRVMs were transfected with SUV39H siRNA or random siRNA (SCR) followed by treatment with H2O2. ChIP assays were
performed with indicated antibodies (d). SIRT1 expression was examined by qPCR (e) and western blotting (f). (g–i) MI was induced in Suv39h1knockout
(h1 / ) mice, Suv39h2 knockout (h2 / ) mice or wide-type (WT) littermates by LAD. ChIP assays were performed with indicated antibodies (g). SIRT1
expression was examined by qPCR (h) and western blotting (i). Error bars represent s.d. (N¼ 3 for each group). *Po0.05; **Po0.01 (one-way ANOVA
with post hoc Scheffe test).
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Figure 7 | SUV39H inhibition normalizes SIRT1 transcription. (a–c) Primary NRVMs were treated with AAþ 2-DG or chaetocin. ChIP assays were
performed with indicated antibodies (a). SIRT1 expression was examined by qPCR (b) and western blotting (c). (d–f) Primary NRVMs were treated with
H2O2 or chaetocin. ChIP assays were performed with indicated antibodies (d). SIRT1 expression was examined by qPCR (e) and western blotting (f).
(g–i) C57/BL mice were injected peritoneally with chaetocin (25mg kg 1) or DMSO 2 days prior to the LAD procedure. ChIP assays were performed with
indicated antibodies using heart homogenates (g). SIRT1 expression was examined by qPCR (h) and western blotting (i). Error bars represent s.d. (N¼ 3 for
each group). *Po0.05; **Po0.01 (one-way ANOVA with post hoc Scheffe test).
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Figure 8 | SUV39H regulates ROS generation in a SIRT1-dependent manner. (a–c) Primary NRVMs were transfected with SUV39H siRNA, SIRT1 siRNA
or random siRNA (SCR) followed by treatment with AAþ 2-DG. Expression of anti-oxidant genes was examined by qPCR (a) and western blotting (b).
Intracellular ROS levels were examined by DHE staining (c). Scale bar, 20mm. (d–f) Primary NRVMs were transfected with SIRT1 siRNA, or random siRNA
(SCR) followed by treatment with AAþ 2-DG or chaetocin. Expression of anti-oxidant genes was examined by qPCR (d) and western blotting (e).
Intracellular ROS levels were examined by DHE staining (f). Scale bar, 20mm. Error bars represent s.d. (N¼ 3). *Po0.05 (one-way ANOVA with post hoc
Scheffe test).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14941


































































































































































































































































































































































































h1 siSirt1 MI (N=5)
h2 MI (N=5)



































Figure 9 | SUV39H regulates myocardial infarction by targeting SIRT1 in mice. Suv39h1 knockout (h1 / ) mice, Suv39h2 knockout (h2 / ) mice or
wide-type (WT) littermates were injected via tail vein siRNA targeting SIRT1 or scrambled siRNA (SCR) followed by the LAD procedure to induce MI.
(a) Representative TTC staining. Infarct size was calculated and quantified by Image Pro. Error bars represent s.d. (N¼ 5 for each group). (b,c) EF and FS
values were measured by echocardiography. Error bars represent s.d. (N¼ 3 for the sham group and N¼ 5 for each of the MI groups). (d,e) Expression
levels of anti-oxidant genes were measured by qPCR (d) and western blotting (e). Error bars represent s.d. (N¼ 3 for the sham group and N¼ 5 for each of
the MI groups). (f) Cardiac ROS levels were evaluated by DHE staining. Scale bar, 50mm.*Po0.05; **Po0.01 (one-way ANOVA with post hoc Scheffe test).
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Figure 10 | Cardioprotective effects of chaetocin depends on SIRT1 in mice. C57/BL mice were injected peritoneally with chaetocin (25mg kg 1) or
DMSO 2 days prior to the LAD procedure. At the same time, these mice were injected via tail vein siRNA targeting SIRT1 or scrambled siRNA (SCR).
(a) Representative TTC staining. Infarct size was calculated and quantified by Image Pro. (b,c) EF and FS values were measured by echocardiography.
(d,e) Expression levels of anti-oxidant genes were measured by qPCR (d) and western blotting (e). (f) Cardiac ROS levels were evaluated by DHE staining.
Scale bar, 50mm. Error bars represent s.d. (N¼8 for each group). *Po0.05; **Po0.01(one-way ANOVA with post hoc Scheffe test).
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oxidant genes were significantly downregulated (Fig. 9d,e).
In addition, Sirt1 depletion re-instated the intracellular ROS
levels to those observed in wild-type hearts (Fig. 9f). Similarly, we
found that the post-MI benefits associated with SUV39H
deficiency in mice were largely gone by EX-6527 injection
(Supplementary Fig. 30). Of note, the cardioprotective effects of
chaetocin was also dependent on SIRT1 since Sirt1 depletion
(Fig. 10) or inhibition (Supplementary Fig. 31) abrogated the
reduction of infarction size, the normalization of heart function,
the changes in anti-oxidant gene expression, and the suppression
of ROS levels induced by chaetocin in post-MI mice. Collectively,
these data demonstrate that SUV39H regulates ROS generation in
a SIRT1-dependent manner.
Discussion
During MI pathogenesis, a host of insults collectively inflict
damages on cardiomyocytes contributing to the loss of heart
function, acute cardiac arrest and death. We present evidence that
the histone H3K9 trimethyltransferase SUV39H links SIRT1
trans-repression to myocardial infarction. Using H3K9 trimethy-
lation as a readout, Greiner et al.17 have discovered chaetocin as a
specific SUV39H inhibitor. Chaetocin has since been shown to
confer protection against hepatoma18 and leukaemia19 in mice
although the mechanisms seem to be multifold. It remains
ambiguous whether the effects of chaetocin are entirely mediated
through SUV39H and the specificity of chaetocin has been called
into question20. Similar to our study, Schweizer et al.21 have
reported that chaetocin administration is associated with
neuroprotection in an in vitro model of cerebral ischaemia. In
addition, these authors demonstrated that chaetocin treatment
activates the transcription of neurotrophin genes (BDNF) at least
in part by stimulating H3K9 acetylation across the BDNF
promoters. These data echo our own observation that chaetocin
protects ischaemia-challenged cardiomyocytes by epigenetically
activating Sirt1 transcription (Fig. 7) and suggest that at least in
the context of ischaemia-induced cell damages, chaetocin may be
equivalent to SUV39H silencing/depletion.
More recently, Cotman and colleagues have identified
SUV39H-mediated H3K9 trimethylation as a critical link between
ageing and memory loss in mice22. Of importance, this group of
investigators exploited a more selective SUV39H inhibitor called
ETP69 to show that SUV39H inhibition significantly improved
learning of complex task in aged mice. Not coincidently, MI
occurs predominantly in the aged population. In the light of our
finding that chaetocin injection ameliorates the loss of heart
function following MI in mice (Fig. 4), these observations
collectively allude to a scenario wherein SUV39H modulates
ageing-related pathophysiological processes by epigenetically
regulating key transcription events. Indeed, a report by
Liu et al.23 indicates that SUV39H1 deficiency circumvents
premature ageing in Zmpste24 / mice that model the
Hutchinson–Gilford progeria syndrome in humans, offering
strong support for the argument that SUV39H activity
promotes ageing and ageing-associated organ dysfunctions such
as dementia and MI.
Curiously, Schweizer et al. and Liu et al. only examined
systemic levels of H3K9Me3, which from a transcriptional
perspective bears little, if any, relevance to the actual molecular
proceedings underlying disease pathogenesis. A couple of
investigations profiling genome-wide patterns of H3K9Me3
enrichment have offered conflict but insightful snapshots at the
role of SUV39H in different pathobiological processes. Using
hippocampus from acutely stressed Sprague-Dawley rats, Hunter
et al. showed while the transposable and repeated regions saw a
significant increase in H3K9Me3 binding upon stress, little
change was found for H3K9Me3 in the gene body (for example,
promoter regions)24, suggesting that SUV39H most likely plays a
very limited role regulating transcription in the euchromatin
region. In contrast, a group led by Casaccia has reported that
during oligodendrocyte differentiation, a vast majority of
H3K9Me3 can be mapped to the gene body encoding proteins
involved in neuronogenesis25. We show here that SUV39H
expression/activity is intimately connected to Sirt1 promoter-
specific H3K9Me3 levels. In addition, we show that HP1g, but not
HP1a or HP1b, co-regulates SIRT1 trans-repression with
SUV39H. Unlike HP1a or HP1b, HP1g is exclusively situated
in the euchromatin region26. These data suggest that SUV39H
may regulate euchromatin transcription in a tissue- and context-
specific manner likely guided by HP1g. ChIP-seq analyses
performed in healthy and infarcted myocardium may help
clarify this issue and assign a more precise role for SUV39H in
MI pathogenesis.
An intriguing observation here is that Suv39h1 deficiency seems
to confer bigger advantage to mice in terms of survival, infarct size,
post-MI heart function and ROS levels than Suv39h2 deficiency
(Fig. 3), all of which could probably be attributed to the fact that
SUV39H1 acts as a more potent repressor of Sirt1 transcription
(Figs 5 and 6). In response to MI-relevant stress stimuli, the
expression of SUV39H1 and SUV39H2 was altered with distinctive
kinetics: SUV39H1 upregulation was more persistent while
SUV39H2 upregulation was more transient (Figs 1 and 2). In
addition, HP1g appears to preferentially interact with SUV39H1 on
the Sirt1 promoter (Supplementary Fig. 10), which may also explain
why SUV39H1 played a more dominant role in SIRT1 trans-
repression. It has been previously shown that SUV39H1 and
SUV39H2 redundantly maintain global H3K9Me3 levels, which are
completely erased in SUV39H1/H2 double knockout (DN) mice27.
It remains to be elucidated how SUV39H1 and SUV39H2
differentially bind to target genes to regulate MI pathogenesis.
SUV39H2 only shares B60% amino-acid sequence identity with
SUV39H1 with a highly variable N-terminal domain and the
structural differences may determine target promoter selection by
SUV39H1 and SUV39H2 (ref. 28). Alternatively, SUV39H1 and
SUV39H2 may have non-overlapping lists of binding partners,
which in turn may steer them to different chromatin regions to
regulate transcription, because of distinct structures. A recent report
by the Jenuwein group provides some support for this model:
SUV39H-depednent heterochromatin formation relies on the
sequence-specific transcription factors PAX3 and PAX9 that bind
preferentially to the intergenic satellite repeats29. Since the PAX
family of proteins including PAX3 and PAX9 possess well-defined
functions in regulating a range of pathophysiological processes in
the cardiovascular system30, we suspect a similar scheme may exist
in the euchromatin region to control SUV39H target selection.
At the cellular level, we focused on the role of SUV39H in
regulating ROS levels in cardiomyocytes, which is unlikely to
reflect in full the realm that SUV39H reigns with regards to MI
pathogenesis. For instance, lymphocyte mediated immune
response plays a pivotal role in regulating MI pathogenesis
encompassing injury, healing and remodelling31. By directly
regulating the transcription of lineage specification genes,
SUV39H1 has been show to strike a balance between different
T-lymphocyte subsets32. In addition, SUV39H1 has also been
shown to impact B-lymphocyte-dependent humoral immune
response by modulating class switch recombination33. These
observations highlight a potential role for SUV39H in shaping up
the immune response during MI pathogenesis. Furthermore, a
string of recent reports have put SUV39H at center stage in
regulating stem cell phenotype34–36, an increasingly promising
target for improving post-MI heart function. Of interest, bone
marrow transplantation experiments (Supplementary Figs 7 and 8)
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indicate that myeloid-derived SUV39H is unlikely to play a major
role in MI pathogenesis. SUV39H has been reported to repress
the transcription of p21 (ref. 37) and PML-RAR38 target genes in
macrophages although relatively little is known regarding the
systemic regulatory role of SUV39H in myeloid cells in the
context of MI. Further confounding the link between SUV39H
and SIRT1 is the inherent weakness of some of our
methodologies. In addition to the systemic, instead of lineage-
specific, knockout models, we have used tail vein injection to
deliver siRNAs, which may lodge in tissues and organs other than
the heart such that a definitive relationship between SUV39H and
SIRT1 cannot be taken for granted. Clearly, the cell-specific roles
of SUV39H in MI pathogenesis should be revisited taking into
account of the aforementioned possibilities when conditional
knockout animals are made available.
Previous investigations have examined the functional relation-
ship between SUV39H1 and SIRT1 in different contexts. For
instance, Murayama et al.39 have reported that SIRT1 forms a
co-repressor complex with SUV39H1 to repress the transcription
of rRNA in response to intracellular energy status. SIRT1 has also
been found to cooperate with SUV39H1 to modulate the
chromatin structure surrounding the leukaemic genes and
prevent MLL-rearranged leukaemia40. Vaquero et al. have
shown that SIRT1 could directly modify (deacetylate) and
thus stabilize SUV39H1 to maintain the integrity of
heterochromatin41,42. Our finding adds an additional layer to
the intricate SIRT1–SUV39H1 interplay. It would be of key
interest to see how these different modes of actions dynamically
contribute to the regulation of ischaemic heart disease.
In summary, our data demonstrate the potential of SUV39H
deletion/inhibition in alleviating damages associated with MI. A
genomewide search for more SUV39H targets, using both RNA-seq
and ChIP-seq techniques, in different types of cells in the context of
MI would hopefully clear the lingering uncertainties and render a
more rationalized decision to target SUV39H for drug development.
Methods
Cell culture and treatment. Immortalized rat myoblast cells (H9C2, ATCC
CRL-1446) were maintained in DMEM (Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Hyclone). Primary rat NRVMs were isolated from 1-day-old
Sprague-Dawley rats by digestion with type 2 collagenase. Cells were cultured in
serum-free insulin-transferrin (IT) medium (21) for an additional 24–36 h (ref. 43).
Antimycin (AA), 2-deoxy glucose (2-DG), and hydrogen peroxide (H2O2) and
chaetocin were purchased from Sigma.
Plasmids and transient transfection. Myc-tagged SUV39H1 expression con-
structs41, HA-tagged HP1 expression constructs44 and SIRT1 promoter-luciferase
construct45 have been previously described. Small interfering RNA (siRNA)
sequences were as follows: for Suv39h1, 50-ccacggcagaaucuaaautt-30 ; for Suv39h2,
50-ggaccugauugucccaauatt-30 ; for Hp1a, 50-GCUUUGAGAGAGGACUGGAA
CTT-30; for Hp1b, 50-GACUCCAGUGGAGAGCUCAUGTT-30 ; for Hp1g, 50-
GAGGCAGAGCCUGAAGAAUTT-30 and for Sirt1, 50-CACCUGAGUUGGAUG
AUAUTT-30 . Transient transfections were performed with Lipofectamine 2000
(Invitrogen). Luciferase activities were assayed 24–48 h after transfection using a
luciferase reporter assay system (Promega). Experiments were routinely performed
in triplicate wells and repeated three times.
Mice. Suv39h1 knockout and Suv39h2 knockout mice have been previously
described27. All protocols were approved by the intramural Committee on Ethic
Conduct of Animal Studies of Nanjing Medical University. MI was induced by
permanent ligation of the LAD coronary artery in male, 8-week-old mice. Briefly,
the mice were anaesthetized with a mixture of ketamine (120mg kg 1) and
xylazine (6mg kg 1), the hearts were exposed and the LAD was ligated with a 6-0
prolene suture. The control mice were sham operated wherein the ligature around
the LAD was not tied. Post-MI heart functions were evaluated by echocardiography
(GE Vivid 7 equipped with a 14-MHz phase array linear transducer, S12, allowing a
150 maximal sweep rate). Myocardial infarct size was determined by Evans blue/
triphenyltetrazolium chloride (TTC) staining46. Briefly, the hearts were perfused
with saline on a Langendorff system to remove blood and then stained with with
1% Evans blue followed by incubation in 1% TTC-Tris solution) for 15 min at
37 C. For ROS measurements, frozen heart sections (4 mm) were stained with DHE
(2 mmol l 1, Sigma) in a light-protected humidified chamber at 37 C for 15min.
The slides were visualized by co-focal fluorescence microscopy (Zeiss). To examine
cardiomyocyte apoptosis, frozen heart sections (4-mm) were stained using a
TUNEL kit (Roche) and the nuclei were counter-stained with DAPI (Sigma). The
slides were visualized by co-focal fluorescence microscopy (Zeiss).
Protein extraction and western blot. Whole-cell lysates were obtained by
re-suspending cell pellets in RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 1%
Triton X-100) with freshly added protease inhibitor cocktail tablet (Roche).
Western blot analyses were performed with anti-Suv39h1 (Proteintech, 10574-1,
1:1,000), anti-Suv39h2 (Genetex, GTX129167, 1:1,000), anti-HP1a (Proteintech,
11831-1, 1:1,000), anti-HP1b (Proteintech, 10241-1, 1:1,000), anti-HP1g (Pro-
teintech, 11650-2, 1:1,000), anti-SOD1 (Proteintech, 10269-1, 1:1,000), anti-SOD2
(Proteintech, 24127-1, 1:1,000), anti-catalase (Proteintech, 21260-1, 1:1,000), anti-
a-SMA (Sigma, F3777, 1:5,000), anti-SIRT1 (Abcam, ab110304, 1:2,000), anti-
collagen type I (Rockland, 001-001-103, 1:2,000), RNA Polymerase II (Santa Cruz,
SC-899, 1:2,000) and anti-b-actin (Sigma, A5441, 1:5,000) antibodies. Uncropped
western blots are presented in Supplementary Fig. 32.
RNA isolation and real-time PCR. RNA was extracted with the RNeasy RNA
isolation kit (Qiagen). Reverse transcriptase reactions were performed using a
SuperScript First-strand Synthesis System (Invitrogen). Real-time PCR reactions
were performed on an ABI Prism 7500 system. Primers and Taqman probes used
for real-time reactions were purchased from Applied Biosystems.
ChIP and Re-ChIP. ChIP and Re-ChIP assays were performed as previously descri-
bed47–49. Aliquots of lysates containing 200mg of protein were used for each
immunoprecipitation reaction with anti-SUV39H1 (Abcam, ab12405, 5mg per
reaction), anti-SUV39H2 (Abcam, ab5264, 5mg per reaction), anti-trimethylated H3K9
(Abcam, ab8898, 2mg per reaction), anti-acetyl H3K9 (Abcam, ab10812, 2mg per
reaction), anti-HP1a (Abcam, ab10811, 5mg per reaction), anti-HP1b (Abcam,
ab77256, 5mg per reaction) and anti-HP1g (Abcam, ab154871, 5mg per reaction). For
re-ChIP, immune complexes were eluted with the elution buffer (1% SDS, 100mM
NaHCO3), diluted with the re-ChIP buffer (1% Triton X-100, 2mM EDTA, 150mM
NaCl, 20mM Tris pH 8.1), and subject to immunoprecipitation with a second antibody
of interest. Precipitated genomic DNA was amplified by real-time PCR with the
following primers: Sirt1 promoter region ( 182/þ 56), 50-GCCATCGCAAACTTG
AACCACC-30 and 50-CGTCCGCCATCTTCCAACTGC-30 ; Gapdh promoter region
( 225/þ 31), 50-ATCACTGCCACCCAGAAGACTGTGGA-30 and 50-CTCATACC
AGGAAATGAGCTTGACAAA-30 ; Sod1 promoter region ( 212/þ 18), 50-AATAG
CGACTTTCCCAGCTC-30 and 50-AAACGAAGGTGCAAAACGAG-30 .
Statistical analysis. Animal numbers and sample sizes reflected the minimal
number needed for statistical significance based on power analysis and prior
experience. No data were excluded from any of the experiments. Grouping was
performed in a randomized manner. Blinding were not performed because it was
not appropriate for the types of animal groups used here, or the types of com-
parisons used between groups. One-way analysis of variance with post hoc Scheffe
analyses were performed using an SPSS package. Mouse survival data was analysed
by the Kaplan–Meier log-rank test.
Data availability. All data generated or analysed during this study are included in
this published article and its Supplementary Information files, or are available from
the corresponding author on reasonable request.
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